

7th World Congress on

Pharmacological and Toxicological Studies

Dec 14, 2022 | Webinar

Received date: 07-10-2022 | Accepted date: 10-10-2022 | Published date: 30-12-2022

Recent Advancements in Pharmacovigilance

Sara G

Clin Group Holding, Beirut

Pharmacovigilance is defined as the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other medicinerelated problem. Recent studies have shown that artificial intelligence, which is based on machine learning, has a large impact on pharmacovigilance. For products already in the market and pharmaceuticals in development, artificial intelligence may be used to select pharmacovigilance tasks, characterize differences with other fields, and identify opportunities for improvement. The majority of studies have shown that artificial intelligence has been used to identify safety signals through automated processes and training with machine learning models by processing and analyzing large amounts of data. In addition, recent analysis has revealed that newer methods such as deep learning have been increasingly used. The automation and machine learning models can optimize pharmacovigilance processes and provide a more efficient way to analyze information relevant to safety, although more research is needed to identify if this optimization has an impact on the quality of

safety analyses.

Recent Publications

- Pascale Olivier, Jean-Louis Montastruc The nature of the scientific evidence leading to drug withdrawals for pharmacovigilance reasons in France Wiley Online Library 15 May 2006
- Amelle Mouffak, Marion Lepelley & Bruno Revol High prevalence of spin was found in pharmacovigilance studies using disproportionality analyses to detect safety signals: a meta-epidemiological study Journal of Clinical Epidemiology VOLUME 138, P73-79, OCTOBER 01, 2021.

Biography

Sara G has completed her Doctor of Pharmacy and master's in clinical pharmacy and pharmacoepidemiology from Lebanese University, Lebanon. She has worked as a licensed pharmacist in a well-known community pharmacy, then as an associate editor in a European pharmacy journal and finally as a pharmacy consultant in an international research company. Her passion to research has led her to excel in her thesis presentation titled "Adverse Drug Events of CDK4/6 Inhibitors in Metastatic Breast Cancer" and given her a variety of opportunities, especially in Pharmacovigilance.

Saraghaith123@gmail.com